HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept by Jigal Haas et al.
Haas et al. Journal of Ovarian Research 2014, 7:35
http://www.ovarianresearch.com/content/7/1/35BRIEF COMMUNICATION Open AccessHCG (1500IU) administration on day 3 after
oocytes retrieval, following GnRH-agonist trigger
for final follicular maturation, results in high
sufficient mid luteal progesterone levels - a proof
of concept
Jigal Haas1,2, Alon Kedem1,2, Ronit Machtinger1,2, Shir Dar1,2, Ariel Hourvitz1,2, Gil Yerushalmi1,2 and Raoul Orvieto1,2*Abstract
Background: Controlled ovarian hyperstimulation (COH) which combining GnRH antagonist co-treatment and
GnRH agonist trigger with an additional 1500 IU hCG luteal rescue on day of oocytes retrieval, has become a
common tool aiming to reduce severe ovarian hyperstimulation syndrome (OHSS). In the present, proof of concept
study, we evaluate whether by deferring the hCG rescue bolus for 3 days, we are still able to rescue the luteal phase.
Methods: Patients undergoing the GnRH-antagonist protocol, who were considered at high risk for developing severe
OHSS and received GnRH-agonist for final oocyte maturation, were included. For luteal phase support, all patients
received an “intense” luteal support. Those who had no signs of early moderate OHSS on day 3 after oocytes retrieval
were instructed to inject 1500 IU of HCG bolus (hCG group). Ovarian stimulation characteristics and mid luteal
progesterone levels were compared between those who received the HCG bolus and those who did not.
Results: Eleven IVF cycles were evaluated, 5 in the hCG group and 6 in the intense luteal support only group. While no
in-between group differences were observed in ovarian stimulation characteristics, significantly higher mid luteal
progesterone levels (>127 nmol/L vs 42.1 ± 14.5 nmol/L, respectively) and a non-significant increase in pregnancy rate
(40% vs 16.6%, respectively), were observed in those who receive the hCG bolus compared to those who did not.
Conclusions: hCG luteal rescue should be offered 3 days after oocytes retrieval only to those patients with no signs of
early moderate OHSS. Further studies are required to elucidate the appropriate regimen of luteal HCG administration in
patients undergoing final follicular maturation with GnRH-agonist.
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Ovarian hyperstimulation syndrome (OHSS) is a serious
complication of ovulation induction, almost always pre-
sents either after human chorionic gonadotropin (hCG)
administration in susceptible patients or during early
pregnancy. Despite many years of clinical experience,
the pathophysiology of OHSS is poorly understood and
there is no reliable test to predict patients who will* Correspondence: raoul.orvieto@sheba.health.gov.il
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unless otherwise stated.subsequently develop severe OHSS [1]. Of notice, that
while investigating randomized controlled trials that
aimed to prevent of severe OHSS, we found that different
studies defined high-risk patients by different estradiol
(E2) threshold levels, ranging from 1906 to 6000 pg/ml,
most used a level of ~3000 pg/ml [2]. Moreover, when all
the predictive variables for severe OHSS were combined,
the prevalence of severe OHSS in the ostensibly high risk
patients was only about 20% [2] an extremely low value
for a good predictive measure (false positive-80%).d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pletely prevent severe OHSS, except for withholding the
ovulation-inducing trigger of hCG, or replacing hCG
with GnRH agonist (GnRHa) to trigger ovulation [3,4].
However, due to the reported significantly reduced clin-
ical pregnancy and increased first trimester pregnancy
loss [5,6] using the GnRH antagonist controlled ovarian
hyperstimulation (COH) protocol with GnRHa trigger,
efforts have been made to improve reproductive outcome,
by manipulating the luteal phase. The three suggested op-
tional strategies aiming to improve outcome are freeze-all
policy; fresh transfer and intensive luteal support; and fresh
transfer and low-dose HCG supplementation [7].
One bolus of 1500 IU hCG 35 h after the triggering
bolus of GnRHa (on day of oocytes retrieval) was dem-
onstrated to rescue the luteal phase, resulting in a re-
productive outcome comparable with that of HCG
triggering, and with no increased risk of OHSS [8,9].
However, in a recently published retrospective study,
Seyhan et al. [10] have challenged the safety of the
GnRHa trigger with HCG rescue. They examined whether
GnRHa trigger and 1500 IU hCG luteal rescue protocol,
completely prevented severe OHSS. Of the 23 patients
evaluated, 6 (26%) developed severe OHSS, 5 of whom
had severe early OHSS requiring ascites drainage and
hospitalization. Figure that is comparable to the afore-
mentioned 20% prevalence of severe OHSS, in high
risk patients.
Since early OHSS occurs 3–7 days following hCG trigger
for final follicular maturation, it is our policy to withhold
the 1500 IU hCG luteal rescue bolus and to follow and re-
evaluate these patients for 3 days after oocyte retrieval
[day of embryo transfer (ET)] for signs of early moderate
OHSS. Only those patients with no signs of early OHSS
are instructed to inject 1500 IU of HCG. By deferring the
hCG bolus by 3 days (5 days following GnRHa trigger), we
believe that we are actually offering the hCG to 80% of the
a priori at risk patients (the aforementioned- detection
rate c’ 80% false positive), who are not supposed to de-
velop severe early OHSS, while avoiding hCG luteal
rescue to the “real” 20-26% [2,10] patient at risk to develop
severe early-OHSS.
The main criticism of the aforementioned protocol,
that we aimed to challenge in the present proof of concept
study, is whether by deferring the hCG rescue bolus
for 3 days, we are still able to rescue the luteal phase,
as evident by sufficient mid luteal progesterone levels,
without jeopardizing pregnancy rate or increasing the
risk for severe OHSS.
Methods
We reviewed the computerized files of all consecutive
women admitted to our in-vitro fertilization (IVF) unit
from August 2013 to December 2013 who reached theoocyte retrieval stage. Only those patients undergoing
the multiple-dose GnRH-antagonist protocol, who were
considered at high risk of developing severe OHSS, i.e.
those with rapidly rising serum E2 levels; peak E2 level
in excess of 9175 pmol/L (2,500 pg/mL); and/or the
emergence of a large number of intermediate sized fol-
licles [11] and received 0.2 mg triptorelin (Decapeptyl,
Ferring, Malmo, Sweden) for final oocyte maturation,
were included. The study was approved by our institutional
review board (IRB number 0776-13-SMC).
For luteal phase support, all patients received an “intense”
luteal support [12], starting 1 day after oocyte retrieval,
that included 4 mg daily E2 valerate per os (Progynova;
Schering), combined with either 50 mg progesterone IM
(Gestone, Ferring- Lapidot, Israel) daily, 400 mg micronized
progesterone vaginal tablets (Endometrin, Ferring-Lapidot,
Israel) in two divided doses, or 180 mg micronized
progesterone vaginal gel (Crinone® 8%, Merck Serono,
Herzelia, Israel) in two divided doses.
Three days after oocyte retrieval (day of ET), patients
were evaluated for signs of early moderate OHSS
(ultrasonographic signs of ascites as reflected by the
appearance of fluid surrounding the uterus/ovaries,
and/or hematocrit levels >40% for the degree of hae-
moconcentration). If signs of early moderate OHSS
appeared, one embryo was transferred, and the patient
was instructed to continue with the intense luteal support
only (Intense support only group). If no early signs of
OHSS developed, one embryo was transferred, and the
patient was instructed to continue with the intense luteal
support and to inject 1500 IU of HCG (hCG group).
According to Engmann’s protocol [12], serum proges-
terone levels were measured 4 days after embryo transfer
(One week after oocyte retrieval- mid luteal phase), and
additional IM progesterone was provided to increase serum
progesterone levels if needed.
Data on patient demographics, controlled ovarian
hyperstimulation (COH) characteristics and mid luteal
progesterone levels were recorded and compared between
those who received a bolus of 1500 IU hCG on day of
ET (hCG group) and those who did not (Intense support
only group).
Results are presented as means ± SD. Differences in
variables between the two luteal different luteal sup-
ports were statistically analyzed with Student’s t-test
and Chi-squared test, as appropriate. A p value of less than
0.05 was considered significant.
Results
Eleven IVF cycles in 11 women were evaluated, 5 in the
hCG group (age 31.6 ± 4.6) and 6 in the intense luteal
support only group (age 29.8 ± 5.1). The clinical character-
istics of the IVF cycles in the two study groups are shown
in Table 1.
Table 1 Comparison between IVF cycles with intense luteal support only versus additional luteal hCG
hCG group (n = 5) Intense luteal support group (n = 6) p values
Age (yrs) 31.6 ± 4.6 29.8 ± 5.1 ns
BMI (kg/m2) 23.65 ± 3.8 23.0 ± 2.5 ns
Length of stimulation (days) 9 ± 2.1.8 10.3 ± 3.8 ns
Number of gonadotropin ampoules used 17.1 ± 3.4 22.0 ± 11.5 ns
Peak E2 levels on day of hCG administration (pmol/L) 10597 ± 669 13064 ± 3019 ns
Peak progesterone levels on day of hCG administration (nmol/L) 2.1 ± 0.2 2.3 ± 0.5 ns
Number of oocytes retrieved 18.4 ± 3.5 19.6 ± 3.0 ns
Mid-luteal progesterone levels (nmol/L) >127 42.1 ± 14.5 <0.0001
Pregnancy rate 2/5(40%) 1/6(16.6%) ns
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in patients’ body mass index, the length of ovarian stimula-
tion, number of gonadotropin ampoules used, peak E2 and
progesterone levels on day of hCG administration, nor in
the number of oocytes retrieved (Table 1), mid-luteal
progesterone levels were significantly higher in those who
receive a 1500 IU hCG bolus, as compared to those who
did not (>127 nmol/L vs 42.1 ± 14.5 nmol/L; p < 0.0001,
respectively).
Pregnancy was achieved in 2 patients in the hCG
group (40%) and one in the intense support only group
(16.6%); this difference wasn’t statistically significant.
Regarding severe OHSS, no case of severe OHSS was
reported among the study groups.
Discussion
The key to preventing OHSS is experience with ovulation
stimulation therapy and recognition of “risk factors” for
OHSS. In our practice, normal and high-responder patients
undergoing their first IVF attempt are offered the COH
with a GnRH antagonist [13]. With this strategy we are able
to substitute hCG with the GnRHa to trigger ovulation in
those at risk to develop severe OHSS [11].
In those achieving ≥20 oocytes, the freeze all policy
with the subsequent frozen-thawed ET, is usually recom-
mended. However, if less than 20 oocytes are retrieved,
patients are instructed to start an intensive luteal sup-
port with estradiol and progesterone and are evaluated
3 days after oocyte retrieval for signs of early moderate
OHSS. A bolus of 1500 IU hCG is offered only to those
with no signs of early moderate OHSS.
In this small series of 11 patients, we demonstrated that
by deferring the hCG bolus by 3 days (5 days following
GnRHa trigger, instead of day of oocytes retrieval), we are
still able to rescue the corpus luteum, with an observed
extremely high midluteal progesterone levels and with no
cases of severe OHSS. This observation is in accordance
with previous studies, in the human as well as the animal
model, that demonstrated corpus luteum rescue after three
days of LH deprivation [14,15]. Moreover, in their elegantrhesus monkeys model, Hutchinson and Zeleznik have
demonstrated the restoration of gonadotropin secretion
following 3-day gonadotropin deprivation period, dur-
ing the early (days 2–5) and mid (days 8–11) luteal
phase (but not in the late ≥ 13 days), that resulted in
resumption of progesterone secretion which continued
for a period of time which effectively completed the
typical lifespan of the corpus luteum [15].
The mid luteal progesterone levels obtained in our study,
in the intense support only group were 42.1 ± 14.5 nmol/L.
Figure, that is in the lower range for successful implantation
[16]. Moreover, the mid luteal progesterone levels obtained
in our study, in patients receiving the hCG luteal bolus
3 days following oocytes retrieval, are comparable to the
levels obtained in those receiving the hCG luteal bolus on
the day of oocytes retrieval [17].
Moreover, we believe that by doing so, we are actually
offering the hCG to 80% of the a priori at risk patients
(the aforementioned- detection rate c’ 80% false positive),
who are not supposed to develop severe early OHSS, while
avoiding hCG administration to the “real” 20-26% [2,10] pa-
tient at risk to develop severe early-OHSS. Despite a rather
limited experience, no case of OHSS has been encountered
and a reasonable pregnancy rate was achieved (40%).
Following the study by Seyhan et al. [10], demonstrating
an extremely high prevalence of severe OHSS following
1500 IU hCG bolus on day of oocytes retrieval, it seems
that those patients triggered by GnRHa for final oocytes
maturation, remain with two treatment options: (a) the
freeze-all policy- notwithstanding the recent improvement
in live birth rates after replacement frozen-thawed vitrified
oocytes/embryos, it should be emphasized, that in most
centers, there is still a gap in live birth rates between fresh
and frozen/thawed cycles (in favor of fresh cycle); and
(b) intensive luteal support of estradiol and progesterone-
the data regarding the efficacy of this modality are still in-
conclusive. While comparing our experience with GnRHa
trigger before [6] and after modifying our luteal-phase sup-
port to the intensive support with E2 and progesterone, we
could not demonstrate any differences in peak E2 levels,
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ation and pregnancy rates, between the two luteal support
regimens [18]. Moreover, in both groups of luteal support
following GnRH-a trigger, implantation and pregnancy rates
were lower compared to HCG trigger [6,18]. Therefore, the
search for an optimal luteal support regimen to patients
receiving GnRHa trigger should be continued.
In the present study, with its inherent limitation due
to the small sample size, we offer a new treatment modality
that clearly supports the concept of rescuing the corpus
luteum, despite the 3 days delay in hCG administra-
tion (3 days following oocytes retrieval). This delay of-
fers the ability to differentiate between those who will
benefit from hCG without developing severe OHSS
(the 80% false positive) and those who will not. Moreover,
the observed reasonable pregnancy rate achieved, with
no patient developing severe OHSS are promising, and
mandate further large prospective randomized studies.
Conclusions
COH using GnRH antagonist co-treatment and GnRHa trig-
ger, combined with 1500 IU hCG luteal rescue, is a promis-
ing protocol, aiming to reduce (rather than eliminating)
severe early OHSS, in one hand, and to improve repro-
ductive outcome, in the other. However, according to
the present proof of concept study, in the meantime and
until further prospective randomized studies elucidating
the appropriate dose and timing of HCG administration
will appear, we believe that hCG luteal rescue should be
offered 3 days after oocytes retrieval only to those patients
with no signs of early moderate OHSS [13].
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